Read More >
The New York Center for Drug Discovery and Development Symposium
Tuesday December 11, 2012
Free and open to the public
1:30 - 5 p.m.
This symposium presents the power and promise of academic drug discovery and development to translate the research and technologies of universities into new medicine for human diseases — as well as support the growth of regional and global bio economy.
The featured talks by four leading experts in the field provide the latest examples and structural, chemical, and biological perspectives of the close interplay of biomedical research and translational therapeutic development for human diseases. The presenters' expertise includes cancer, disorders of the central nervous system, infectious diseases, and cardiovascular and metabolic diseases.
This symposium is held in conjunction with the opening of the New York Center for Drug Discovery and Development (NYCD3), SUNY Upstate's new center to facilitate the development of academic research discoveries into clinical and commercial applications through collaboration with regional and global medical, business, and industrial communities.
Ziwei Huang, PhD, Upstate Medical University
"Overview of NYCD3 and Drug Discovery and Development at Upstate"
Wayne Hendrickson, PhD, Columbia University
"Conformational Equilibria in the Allosteric Control of Hsp70 Molecular Chaperones"
Victor Hruby, PhD, University of Arizona
"The Impact of Genomics and Proteomics on Drug Design: Design of Multivalent Peptide and Peptidomimetic Ligands for Disease"
Gen-Sheng Feng, PhD, University of California San Diego
"Shp2 in Health and Diseases: From Mechanism to Therapy"
About the Speakers
Prior to joining Upstate in 2009, Dr. Huang was a faculty member at the Burnham Institute for Medical Research and at the University of California at San Diego where he built a robust research program centering on the development of molecular probes that can be transformed into new therapeutic agents for the treatment of cancer. Huang's laboratory has shown that synthetic cell binding peptides can induce destruction of tumor cells and suppress the growth of tumor in mice. In addition, he discovered, using computer-screening techniques, organic compounds that mimic the tumor-killing effect of these binding peptides. Huang is planning further studies to advance these inhibitors to human clinical trials as a new class of anti-cancer drugs. Dr. Huang has lectured worldwide and published more than 100 research articles, reviews, book chapters and conference proceedings. He is editor of the book "Drug Discovery Research: New Frontiers in the Post-Genomic Era."
His honors include the Aminoff Prize of the Royal Swedish Academy of Sciences, the Gairdner International Award, and the Harvey Prize of the Technion – Israel Institute of Technology. He is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences.
Dr. Feng received a PhD degree in Molecular Biology and Microbiology at Indiana University Bloomington. Before joining UCSD, Dr. Feng held faculty positions at Indiana University School of Medicine and the Sanford/Burnham Medical Research Institute. Dr. Feng has published 119 peer-reviewed research papers, review and book chapters. He has served on MCB and JBC editorial boards and NIH study sections.
The symposium will be held on the SUNY Upstate campus in the 9th Floor Auditorium, Weiskotten Hall, 766 Irving Ave, Syracuse, NY.
[ Map and Directions ]
This symposium is jointly sponsored by NYCD3 and the Carol M. Baldwin Breast Cancer Research Fund.
About the NYCD3
The New York Center for Drug Discovery and Development (NYCD3) at Upstate Medical University is a new center to facilitate the development of academic research discoveries into clinical and commercial applications through collaboration with regional and global medical, business, and industrial communities.